	US 11,866,512 B2
	Antibodies to citrullinated proteins
Rikard Holmdahl, Stockholm (SE); Theo Rispens, EB Utrecht (NL); Bingze Xu, Uppsala (SE); and Changrong Ge, Sundbyberg (SE)
Assigned to Vacara AB, Solna (SE)
Appl. No. 16/765,752
Filed by VACARA AB, Solna (SE)
PCT Filed Nov. 22, 2018, PCT No. PCT/EP2018/082236 § 371(c)(1), (2) Date May 20, 2020, PCT Pub. No. WO2019/101863, PCT Pub. Date May 31, 2019.
Claims priority of application No. 1730323-1 (SE), filed on Nov. 22, 2017.
Prior Publication US 2020/0291133 A1, Sep. 17, 2020
Int. Cl. C07K 16/36 (2006.01)

CPC C07K 16/36 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01)]

14 Claims

1. An antibody or antibody fragment comprising a variable heavy chain (VH) domain and a variable light chain (VL) domain, and wherein

(a) the VH domain comprises an amino acid sequence that includes complementarity determining regions (CDRs):

a CDR1 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 1;

a CDR2 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 3; and

a CDR3 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 4 and

(b) the VL domain comprises an amino acid sequence that includes complementarity determining regions (CDRs):

a CDR4 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 5;

a CDR5 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 6; and

a CDR6 sequence comprising an amino acid sequence as set forth in SEQ ID NO: 7.